Author:
Eggermont A. M. M.,ten Hagen T. L. M.
Publisher
Springer Berlin Heidelberg
Reference85 articles.
1. Asher AL, Mule JJ, Reiehert CM, Shiloni E, Rosenberg SA (1987) Studies of the antitumor efficacy of systemically administered recombinant tumor necrosis factor against several murine tumors in vivo. J Immunol 138:963–974
2. Benckhuijsen C, Kroon BB, van Geel AN et al. (1988) Regional perfusion treatment with melphalan for melanoma in a limb: an evaluation of drug kinetics. Eur J Surg Oncol 14:157–163
3. Biekels, J, Manusama, ER, Gutman M et al. (1999) Isolated limb perfusion with tumour necrosis factor-alpha and melphalan for unresectable bone sarcomas of the lower extremity [In Process Citationl. Eur J Surg Oncol 25:509–514
4. Braat RP, Wieberdink J, van Slooten EA, Olthuis G (1983) Regional perfusion with Adriamyein in soft tissue sarcomas. In: Schwemmle K, Aigner K (eds) Vascular Perfusion in Cancer Therapy, Recent Results in Cancer Research search, vol 86, Springer, Berlin Heidelberg New York Tokyo, pp 260–263
5. Brouckaert PGG, Leroux-Rouls GG, Guisez Y Tavernier J, Fiers W (1986) In vivo anti-tumor activity of recombinant human and murine TNF, alone and in combination with IFN-gamma on a syngeneie murine melanoma. Int J Cancer 38:763–769